Retatrutide: what the triple-agonist literature shows
Most people have heard of dual agonists. Retatrutide adds a third receptor to the mechanism — here’s what the Phase 2 data published in NEJM 2023 actually reports.
TL;DR
- Retatrutide is an investigational compound developed by Eli Lilly that targets three hormone receptors simultaneously: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon.
- A Phase 2 trial published in The New England Journal of Medicine in 2023 reported substantial weight reduction versus placebo at 48 weeks across multiple dose groups.
- As of publication date, retatrutide is not FDA-approved for any indication and has not completed Phase 3 trials.
What it is
Retatrutide (LY3437943) is a once-weekly subcutaneous injection in clinical development by Eli Lilly and Company. It is classified as a triple receptor agonist because it activates three distinct hormone receptors: the GLP-1 receptor (also activated by semaglutide and tirzepatide), the GIP receptor (also activated by tirzepatide), and the glucagon receptor — the third arm that distinguishes retatrutide from currently approved dual-agonist compounds. The glucagon receptor plays a role in hepatic glucose production and energy expenditure, which is the physiological rationale for including it in a multi-agonist design. This compound has not received FDA approval for any indication as of the date of this article.
How it works
Each of the three receptor arms contributes distinct signaling. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. GIP receptor activation has been studied for its additive effects on insulin secretion and, in combination with GLP-1 agonism, appears to enhance weight reduction outcomes compared to either alone. Glucagon receptor activation increases hepatic glucose output and metabolic rate — which, in the context of the other two agonist arms, researchers hypothesize may enhance energy expenditure without the hyperglycemic effect that isolated glucagon stimulation would produce. The combined pharmacology is complex, and the clinical implications of the glucagon component are still being characterized in ongoing studies.
Who asks about it
People come to this topic after encountering references to retatrutide in health journalism or popular podcasts that discuss the next generation of metabolic compounds. The question is typically: “Is this meaningfully different from what’s already available, and what does the actual data show?” That’s a reasonable question — and the honest answer is that Phase 2 data, while promising in direction, does not constitute the same evidence base as a completed Phase 3 program.
What the research says
Jastreboff et al. published Phase 2 results in The New England Journal of Medicine in 2023. The trial enrolled adults with a BMI of 27 or higher and randomized them to varying doses of retatrutide or placebo over 48 weeks. At the highest doses studied (12 mg weekly), mean weight reduction versus placebo was reported in a range that exceeded outcomes previously observed in single-agent GLP-1 trials, though cross-trial comparisons have significant methodological limitations. The study was not powered for cardiovascular or long-term safety endpoints. Adverse events included GI effects consistent with the GLP-1 agonist class — nausea, vomiting, diarrhea — as the most commonly reported. Phase 3 trials are ongoing as of this publication.
What to know before considering it
Retatrutide is not available as an FDA-approved drug. Any compounded formulation using retatrutide as an active ingredient would require evaluation under applicable compounding pharmacy regulations, and access is subject to significant regulatory complexity. Do not confuse investigational compound availability with approval status. Any discussion about retatrutide in a clinical context requires a licensed clinician familiar with the current regulatory status.
The Halftime POV
The triple-agonist mechanism is a genuinely interesting scientific development — it reflects how researchers are thinking about metabolic dysfunction as a multi-pathway problem that may respond to multi-pathway interventions. The Phase 2 data warrants attention. But Phase 2 is not Phase 3, and Phase 3 is not clinical practice. Understanding what stage the evidence is at is more useful than either dismissing it or treating preliminary findings as settled science.
Related reading:
FAQ
Q: What is retatrutide? A: Retatrutide is an investigational triple agonist targeting three receptors simultaneously: GLP-1R, GIPR (GIP receptor), and glucagon receptor. It is being developed by Eli Lilly. A Phase 2 trial published in the New England Journal of Medicine in 2023 reported substantial weight reduction in participants with obesity.
Q: How does retatrutide differ from semaglutide or tirzepatide? A: Semaglutide targets GLP-1R only. Tirzepatide targets GLP-1R and GIPR (dual agonist). Retatrutide adds glucagon receptor agonism, which increases energy expenditure and may enhance fat oxidation. The Phase 2 data suggested higher weight reduction percentages than observed in comparable semaglutide trials, though cross-trial comparisons have methodological limitations.
Q: Is retatrutide available as a compounded medication? A: As of April 2026, retatrutide is investigational — it has not received FDA approval and is not available as a prescription medication or as a compounded product. It remains in clinical trials. Compounding pharmacies cannot legally compound a drug that has not been approved and has no active pharmaceutical ingredient designation.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Note on ongoing litigation: Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory landscape for compounded GLP-1 formulations continues to evolve.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” NEJM, 2023
- Eli Lilly. Retatrutide clinical development pipeline. LillyTrials.com
- ClinicalTrials.gov. “A Study of Retatrutide (LY3437943) in Participants With Obesity.” NCT05882045
